More Articles

Recall of anaemia drug highlights safety issues of NBCDs Biosimilars/General | Posted 05/04/2013

US-based biotech firm Affymax announced on 24 February 2013 that it is recalling all lots of its red blood cell-stimulating medicine Omontys (peginesatide).  This could have broader implicatio...

US FTC sides with generics makers over drug samples Policies & Legislation | Posted 05/04/2013

The US Federal Trade Commission (FTC) has come out in support of generics companies trying to get hold of brand-name drugs in order to make generic versions.

Huge differences in prescription drug prices in Ireland Reports | Posted 05/04/2013

A survey carried out by Ireland’s National Consumer Agency (NCA) has found that the price of many commonly prescribed medicines varies widely across Ireland.

Amgen’s biosimilar plans Biosimilars/News | Posted 05/04/2013

Amgen was one of the first companies to recognize the potential of modern biotechnology and this has made it the world’s largest independent biotechnology firm.

Mylan launches generics and reaches settlement over metformin Generics/News | Posted 05/04/2013

Generics giant Mylan has launched generic versions of fenofibrate capsules, cidofovir injection and levalbuterol. The company has also resolved patent litigation with Shionogi and Andrx related to...

Research on biosimilars in anaemia and diabetes Biosimilars/Research | Posted 05/04/2013

Period: September to December 2012 The use of biological medicines has been life-changing for many patients suffering with anaemia and diabetes. With the expiration of patents on these biologi...

Report on 25th Annual EuroMeeting, 4-6 March 2013, Amsterdam, The Netherlands Conferences | Posted 05/04/2013

Delegates at DIA’s 25th Anniversary of the EuroMeeting, held on 4–6 March 2013 in Amsterdam, The Netherlands, were offered the mouth watering prospect of more than 100 sessions across 17 themes, ad...

Biosimilars in rheumatology Biosimilars/Research | Posted 29/03/2013

Patents on key biological medicines used in rheumatology will expire soon. The European Medicines Agency’s (EMA’s) finalized guidelines on biosimilar monoclonal antibodies (mAbs) came into effect o...